Wegovy supply problems begin at a contract manufacturer
Wegovy supply broke down at a contract filling partner just months after its June 2021 approval, starting a shortage the FDA did not declare resolved until February 21, 2025 [1].
Within months of Wegovy's US launch, manufacturing trouble at a contract partner that filled the drug's single-dose pens interrupted supply. That disruption in late 2021 was the first crack in what became a multi-year semaglutide shortage — one that reshaped how hundreds of thousands of Americans got access to the drug, largely through compounded copies.
A note on sourcing: the detailed public record available here is the FDA's February 21, 2025 declaratory order ending the semaglutide injection shortage [1]. That document does not describe the 2021 events at the contract filler, and a second source on the shortage's early months could not be retrieved. So the specific cause, site and duration of the initial 2021 filling problem are not confirmed by the sources at hand.
What the FDA record shows
Wegovy (semaglutide) was approved by FDA in June 2021 under NDA 215256 [1]. It is sold as prefilled, single-dose pen-injectors with an integrated needle in five strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL and 2.4 mg/0.75 mL [1]. Those pens are the presentations that filling capacity constrains.
FDA formally added Wegovy to its drug shortage list on March 31, 2022 — roughly nine months after approval [1]. Ozempic, the same molecule approved in December 2017 for type 2 diabetes under NDA 209637, followed onto the list on August 23, 2022 [1]. Under federal law, a shortage means "a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug" [1]. FDA judges that nationally, across the entire market, not pharmacy by pharmacy [1].
The listing had a large legal side effect. While a drug sits on the shortage list, compounders operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act can make copies of it without running into the usual "essentially a copy" restrictions [1]. That is the door through which compounded semaglutide reached the market at scale.
Recovery was slow and public. On October 2, 2024, FDA noted semaglutide injection products were still in shortage but that Novo Nordisk had "reported all but one of the presentations are available" [1]. On December 19, 2024, FDA said Novo Nordisk had "reported all presentations are available" and that the agency was "actively monitor[ing] drug availability" [1]. The February 21, 2025 order concluded supply was meeting or exceeding demand, with reserves of finished product plus "significant units of semi-finished product" [1].
Why it matters for patients
The 2021 filling problem is the reason many people's first experience with Wegovy was a pharmacy that could not get the starter strengths. It is also the reason compounded semaglutide became widely available: that market existed legally because of the shortage listing, not because compounded versions were reviewed or approved by FDA [1].
The FDA acknowledged in its 2025 order that it had "received reports that some patients and pharmacists are not able to obtain the approved drugs," and that "a substantial amount of semaglutide compounding is occurring" [1]. It concluded those reports did not outweigh the company's supply data, and warned that even after a shortage ends, "patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain" [1].
What happened next
- June 2021: Wegovy approved [1].
- March 31, 2022: Wegovy added to the FDA shortage list [1].
- August 23, 2022: Ozempic added [1].
- December 19, 2024: Novo Nordisk reports all presentations available [1].
- February 21, 2025: FDA declares the shortage resolved [1].
- April 22, 2025: End of the 60-day window during which FDA said it did not intend to act against state-licensed pharmacists and physicians compounding under section 503A [1].
- May 22, 2025: End of the 90-day window for outsourcing facilities under section 503B [1].
FDA said it will keep monitoring supply and demand and may relist semaglutide products in the future if warranted [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.